Cargando…

Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection

BACKGROUND: Antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 acute infection has increased. Currently, most of the evidence relates to patients in intensive care units; however, there is little information on patients admitted to hospital wards and there is no consensus protocol o...

Descripción completa

Detalles Bibliográficos
Autores principales: Quiros Ambel, Helena, Crespo-Robledo, Paloma, Arribalzaga Juaristi, Karmele, Plo-Seco, Isabel, Martínez Simón, Jose Javier, Pérez Fernández, Elia, Perez Encinas, Monserrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523220/
https://www.ncbi.nlm.nih.gov/pubmed/34649964
http://dx.doi.org/10.1136/ejhpharm-2021-002877
_version_ 1784585254152962048
author Quiros Ambel, Helena
Crespo-Robledo, Paloma
Arribalzaga Juaristi, Karmele
Plo-Seco, Isabel
Martínez Simón, Jose Javier
Pérez Fernández, Elia
Perez Encinas, Monserrat
author_facet Quiros Ambel, Helena
Crespo-Robledo, Paloma
Arribalzaga Juaristi, Karmele
Plo-Seco, Isabel
Martínez Simón, Jose Javier
Pérez Fernández, Elia
Perez Encinas, Monserrat
author_sort Quiros Ambel, Helena
collection PubMed
description BACKGROUND: Antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 acute infection has increased. Currently, most of the evidence relates to patients in intensive care units; however, there is little information on patients admitted to hospital wards and there is no consensus protocol on thromboprophylaxis during admission and after discharge. OBJECTIVE: To assess the effectiveness of antithrombotic prophylaxis in patients admitted with COVID-19 and 30 days after discharge. METHOD: A prospective observational study was conducted of patients admitted with COVID-19 in which the hospital thromboprophylaxis protocol was applied, classifying the patients as having a standard or high risk of thrombosis. Pharmacists performed a daily follow-up and actively intervened during admission and at discharge. The main outcome measure was the global incidence of symptomatic venous thromboembolism (VTE) related to hospitalisation. RESULTS: A total of 113 patients were included, 98.23% of whom were admitted to a hospital ward. The incidence of hospital-acquired VTE was 1.77%. In 75.22% of the subjects, thromboprophylaxis was adjusted to the protocol during admission. A total of 23 pharmaceutical interventions were conducted, with an adherence of 52.17%. At discharge, 94.28% of the patients who had no haemorrhage and ≥4 points on the Padua Prediction Score required thromboprophylaxis, aligning with the protocol. The global incidence of haemorrhagic events during the follow-up period was 0.88%. CONCLUSION: The incidence of hospital-acquired VTE was lower than that described in the literature. Although it cannot be certain that it is directly related to the instituted protocol, the data can show that the management of prevention of VTE is being optimally performed at the hospital. Long-term studies are needed to evaluate the incidence after discharge, as well as to agree on a specific protocol in the COVID-19 population for the prevention of these events during hospitalisation and post-discharge.
format Online
Article
Text
id pubmed-8523220
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-85232202021-10-19 Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection Quiros Ambel, Helena Crespo-Robledo, Paloma Arribalzaga Juaristi, Karmele Plo-Seco, Isabel Martínez Simón, Jose Javier Pérez Fernández, Elia Perez Encinas, Monserrat Eur J Hosp Pharm Original Research BACKGROUND: Antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 acute infection has increased. Currently, most of the evidence relates to patients in intensive care units; however, there is little information on patients admitted to hospital wards and there is no consensus protocol on thromboprophylaxis during admission and after discharge. OBJECTIVE: To assess the effectiveness of antithrombotic prophylaxis in patients admitted with COVID-19 and 30 days after discharge. METHOD: A prospective observational study was conducted of patients admitted with COVID-19 in which the hospital thromboprophylaxis protocol was applied, classifying the patients as having a standard or high risk of thrombosis. Pharmacists performed a daily follow-up and actively intervened during admission and at discharge. The main outcome measure was the global incidence of symptomatic venous thromboembolism (VTE) related to hospitalisation. RESULTS: A total of 113 patients were included, 98.23% of whom were admitted to a hospital ward. The incidence of hospital-acquired VTE was 1.77%. In 75.22% of the subjects, thromboprophylaxis was adjusted to the protocol during admission. A total of 23 pharmaceutical interventions were conducted, with an adherence of 52.17%. At discharge, 94.28% of the patients who had no haemorrhage and ≥4 points on the Padua Prediction Score required thromboprophylaxis, aligning with the protocol. The global incidence of haemorrhagic events during the follow-up period was 0.88%. CONCLUSION: The incidence of hospital-acquired VTE was lower than that described in the literature. Although it cannot be certain that it is directly related to the instituted protocol, the data can show that the management of prevention of VTE is being optimally performed at the hospital. Long-term studies are needed to evaluate the incidence after discharge, as well as to agree on a specific protocol in the COVID-19 population for the prevention of these events during hospitalisation and post-discharge. BMJ Publishing Group 2023-09 2021-10-14 /pmc/articles/PMC8523220/ /pubmed/34649964 http://dx.doi.org/10.1136/ejhpharm-2021-002877 Text en © European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Original Research
Quiros Ambel, Helena
Crespo-Robledo, Paloma
Arribalzaga Juaristi, Karmele
Plo-Seco, Isabel
Martínez Simón, Jose Javier
Pérez Fernández, Elia
Perez Encinas, Monserrat
Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title_full Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title_fullStr Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title_full_unstemmed Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title_short Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection
title_sort effectiveness of antithrombotic prophylaxis in hospitalised patients with sars-cov-2 infection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523220/
https://www.ncbi.nlm.nih.gov/pubmed/34649964
http://dx.doi.org/10.1136/ejhpharm-2021-002877
work_keys_str_mv AT quirosambelhelena effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT cresporobledopaloma effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT arribalzagajuaristikarmele effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT plosecoisabel effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT martinezsimonjosejavier effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT perezfernandezelia effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection
AT perezencinasmonserrat effectivenessofantithromboticprophylaxisinhospitalisedpatientswithsarscov2infection